Achieve Life Sciences appoints Benjamin Halladay as CFO (ACHV:NASDAQ)

H.C. Wainwright reiterated a Buy rating and $12.00 price target for Achieve Life Sciences (ACHV) after 52-week ORCA-OL study data showed 31% of patients achieved smoking abstinence. The stock is up 57% in six months, trading at $6.50. Analysts expect a 2026 NDA resubmission and 2027 approval. ACHV appointed Benjamin Halladay as CFO, with Stifel and Morgan Stanley also initiating coverage with Buy ratings and targets of $18.00 and $13.00, respectively.

Achieve Life Sciences reported 52-week open-label results for cytisinicline, showing 31.2% sustained abstinence at Weeks 49–52, with 39.4% for prior-placebo participants. The Data Safety Monitoring Committee noted no new safety signals. The results support long-term efficacy and safety, according to the company.

ACHIEVE LIFE SCIENCES, INC. (ACHV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Achieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates Closed a private placement of up to $354 million, with $180 million upfront and up to $174 million from warrants exercisable prior to and up to 20 trading days following

Achieve Life Sciences (Nasdaq: ACHV) reported Q2 2026 results and updates on cytisinicline for nicotine dependence. The FDA issued a Complete Response Letter on June 20, 2026 citing cGMP and labeling issues, with no clinical efficacy or safety deficiencies. Achieve closed a private placement up to $354M and expects NDA resubmission in Q4 2026 and potential FDA approval in H1 2027. Cash was $187.3M at June 30, 2026.

Achieve announced it closed a $261.5M securitization of newly originated HELOCs, its first deal of 2026 and ninth overall. The pool covers 3,129 lines with about $261.5M unpaid principal and $276.5M total credit line as of June 30. S&P Global Ratings and Morningstar DBRS assigned ratings to six rated and three unrated note classes.

Achieve Life Sciences (NASDAQ:ACHV) rose 9.3% to $5.38 on Thursday after closing at $4.92; it traded as high as $5.50 on volume of 725,384 shares. Analysts cited mixed views: Canaccord set a $13 target (buy) and HC Wainwright set $12 (buy), while Weiss downgraded to sell (d-). The company reported ($0.19) EPS vs ($0.30) consensus on May 12.